1 Jemal, A. et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225–249 (2009).

2 Scagliotti, G. et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J. Clin. Oncol. 28, 1835–1842 (2010).

3 Pao, W. & Girard, N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12, 175–180 (2011).

4 Mogi, A. & Kuwano, H. TP53 mutations in nonsmall cell lung cancer. J. Biomed. Biotechnol. 2011, 583929 (2011).

5 Makowski, L. & Hayes, D. N. Role of LKB1 in lung cancer development. Br. J. Cancer 99, 683–688 (2008).

6 Varella-Garcia, M. Chromosomal and genomic changes in lung cancer. Cell Adh. Migr. 4, 100–106 (2010).

7 Olaussen, K. A. et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355, 983–991 (2006).

8 Jalal, S., Earley, J. N. & Turchi, J. J. DNA repair: from genome maintenance to biomarker and therapeutic target. Clin. Cancer Res. 17, 6973–6984 (2011).

9 Kastan, M. B. & Bartek, J. Cell-cycle checkpoints and cancer. Nature 432, 316–323 (2004).

10 Pfeifer, G. P. et al. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 21, 7435–7451 (2002).

11 Zhang, N., Liu, X., Li, L. & Legerski, R. Double-strand breaks induce homologous recombinational repair of interstrand cross-links via cooperation of MSH2, ERCC1-XPF, REV3, and the Fanconi anemia pathway. DNA repair (Amst.) 6, 1670–1678 (2007).

12 Chen, C. C., Kennedy, R. D., Sidi, S., Look, A. T. & D'Andrea, A. CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors. Mol. Cancer 8, 24 (2009).

13 Helleday, T., Petermann, E., Lundin, C., Hodgson, B. & Sharma, R. A. DNA repair pathways as targets for cancer therapy. Nat. Rev. Cancer 8, 193–204 (2008).

14 Olivier, M., Hollstein, M. & Hainaut, P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol. 2, a001008 (2010).

15 Peltomäki, P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J. Clin. Oncol. 21, 1174–1179 (2003).

16 Birch, J. M. et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20, 4621–4628 (2001).

17 Wikenheiser-Brokamp, K. A. Retinoblastoma regulatory pathway in lung cancer. Curr. Mol. Med. 6, 783–793 (2006).

18 Lindahl, T. & Wood, R. D. Quality control by DNA repair. Science 286, 1897–1905 (1999).

19 Fagbemi, A. F., Orelli, B. & Schärer, O. D. Regulation of endonuclease activity in human nucleotide excision repair. DNA repair (Amst.) 10, 722–729 (2011).

20 Altaha, R., Liang, X., Yu, J. J. & Reed, E. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int. J. Mol. Med. 14, 959–970 (2004).

21 Simon, G. R., Sharma, S., Cantor, A., Smith, P. & Bepler, G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127, 978–983 (2005).

22 Olaussen, K. A., Fouret, P. & Kroemer, G. ERCC1-specific immunostaining in non-small-cell lung cancer. N. Engl. J. Med. 357, 1559–1561 (2007).

23 Bepler, G. et al. ERCC1 and RRM1 in the international adjuvant lung trial by automated quantitative in situ analysis. Am. J. Pathol. 178, 69–78 (2011).

24 Chen, S., Zhang, J., Wang, R., Luo, X. & Chen, H. The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer 70, 63–70 (2010).

25 Cobo, M. et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J. Clin. Oncol. 25, 2747–2754 (2007).

26 Lord, R. V. et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 8, 2286–2291 (2002).

27 Besse, B. et al. ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy. Ann. Oncol. 22, 575–581 (2011).

28 Zhou, W. et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin. Cancer Res. 10, 4939–4943 (2004).

29 Murphy, C. G. & Moynahan, M. E. BRCA gene structure and function in tumor suppression: a repair-centric perspective. Cancer J. 16, 39–47 (2010).

30 Graeser, M. et al. A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin. Cancer Res. 16, 6159–6168 (2010).

31 Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921 (2005).

32 Shaheen, M., Allen, C., Nickoloff, J. A. & Hromas, R. Synthetic lethality: exploiting the addiction of cancer to DNA repair. Blood 117, 6074–6082 (2011).

33 Rehman, F. L., Lord, C. J. & Ashworth, A. Synthetic lethal approaches to breast cancer therapy. Nat. Rev. Clin. Oncol. 7, 718–724 (2010).

34 Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123–134 (2009).

35 Turner, N., Tutt, A. & Ashworth, A. Hallmarks of 'BRCAness' in sporadic cancers. Nat. Rev. Cancer 4, 814–819 (2004).

36 Lee, M. N. et al. Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer. Clin. Cancer Res. 13, 832–838 (2007).

37 Marsit, C. J. et al. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 23, 1000–1004 (2004).

38 Mendes-Pereira, A. M. et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1, 315–322 (2009).

39 McCabe, N. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66, 8109–8115 (2006).

40 Jin, G. et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer 69, 279–283 (2010).

41 Powell, C. et al. Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers. Cancer Treat. Rev. 36, 566–575 (2010).

42 Liu, S. K. et al. A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother. Oncol. 88, 258–268 (2008).

43 Albert, J. M. et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin. Cancer Res. 13, 3033–3042 (2007).

44 Donawho, C. K. et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res. 13, 2728–2737 (2007).

45 Miknyoczki, S. J. et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol. Cancer Ther. 2, 371–382 (2003).

46 Paul, I. et al. PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer. J. Pathol. 224, 564–574 (2011).

47 Rosell, R. et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PloS ONE 2, e1129 (2007).

48 Bartolucci, R. et al. XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. Clin. Lung Cancer 10, 47–52 (2009).

49 Quinn, J. E. et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 63, 6221–6228 (2003).

50 Chabalier, C. et al. BRCA1 downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 5, 1001–1007 (2006).

51 Stordal, B. & Davey, R. A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1. Curr. Cancer Drug Targets 9, 354–365 (2009).

52 Wang, L. et al. ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel. BMC Cancer 8, 97 (2008).

53 Taron, M. et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum. Mol. Genet. 13, 2443–2449 (2004).

54 Boukovinas, I. et al. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PLoS ONE 3, e3695 (2008).

55 Cobo, M. et al. Spanish customized adjuvant trial (SCAT) based on BRCA1 mRNA levels [abstract]. J. Clin. Oncol. 26 (Suppl. 15), a7533 (2008).

56 Rosell, R. et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PLoS ONE 4, e5133 (2009).

57 Yan, J. et al. The ubiquitin-interacting motif containing protein RAP80 interacts with BRCA1 and functions in DNA damage repair response. Cancer Res. 67, 6647–6656 (2007).

58 Jiricny, J. The multifaceted mismatch-repair system. Nat. Rev. Mol. Cell Biol. 7, 335–346 (2006).

59 Kouso, H. et al. Expression of mismatch repair proteins, hMLH1/hMSH2, in non-small cell lung cancer tissues and its clinical significance. J. Surg. Oncol. 98, 377–383 (2008).

60 Cooper, W. A. et al. Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small-cell lung cancer and precursor lesions. Histopathology 52, 613–622 (2008).

61 Hsu, H. S. et al. Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer. Clin. Cancer Res. 11, 5410–5416 (2005).

62 Scartozzi, M. et al. Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients. Lung Cancer 53, 103–109 (2006).

63 Hsu, H. S., Lee, I. H., Hsu, W. H., Kao, W. T. & Wang, Y. C. Polymorphism in the hMSH2 gene (gISV12–16T > C) is a prognostic factor in non-small cell lung cancer. Lung Cancer 58, 123–130 (2007).

64 Kamal, N. S. et al. MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer. Clin. Cancer Res. 16, 1206–1215 (2010).

65 Martin, S. A. et al. DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1. Cancer Cell 17, 235–248 (2009).

66 Martin, S. A. et al. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol. Med. 1, 323–337 (2009).

67 Kanellis, G. et al. Expression of DNA mismatch repair gene MSH2 in cytological material from lung cancer patients. Diagn. Cytopathol. 34, 463–466 (2006).

68 Wang, Y. C. et al. Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. J. Clin. Invest. 111, 887–895 (2003).

69 Lieber, M. R., Ma, Y., Pannicke, U. & Schwarz, K. Mechanism and regulation of human non-homologous DNA end-joining. Nat. Rev. Mol. Cell Biol. 4, 712–720 (2003).

70 Auckley, D. H. et al. Reduced DNA-dependent protein kinase activity is associated with lung cancer. Carcinogenesis 22, 723–727 (2001).

71 Eriksson, A., Yachnin, J., Lewensohn, R. & Nilsson, A. DNA-dependent protein kinase is inhibited by trifluoperazine. Biochem. Biophys. Res. Commun. 283, 726–731 (2001).

72 Izzard, R. A., Jackson, S. P. & Smith, G. C. Competitive and noncompetitive inhibition of the DNA-dependent protein kinase. Cancer Res. 59, 2581–2586 (1999).

73 Boulton, S., Kyle, S. & Durkacz, B. W. Mechanisms of enhancement of cytotoxicity in etoposide and ionising radiation-treated cells by the protein kinase inhibitor wortmannin. Eur. J. Cancer 36, 535–541 (2000).

74 Zhao, Y. et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res. 66, 5354–5362 (2006).

75 Zheng, Z. et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N. Engl. J. Med. 356, 800–808 (2007).

76 Tooker, P., Yen, W. C., Ng, S. C., Negro-Vilar, A. & Hermann, T. W. Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification. Cancer Res. 67, 4425–4433 (2007).

77 Kwon, W. S. et al. Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet. Genomics 16, 429–438 (2006).

78 Davidson, J. D. et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. 64, 3761–3766 (2004).

79 Bergman, A. M. et al. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res. 65, 9510–9516 (2005).

80 Bepler, G. et al. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J. Thorac. Oncol. 3, 1112–1118 (2008).

81 Ceppi, P. et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann. Oncol. 17, 1818–1825 (2006).

82 Rosell, R. et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 22, 3548–3553 (2003).

83 Rosell, R. et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 10, 1318–1325 (2004).

84 Souglakos, J. et al. Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Br. J. Cancer 98, 1710–1715 (2008).

85 Rosell, R. et al. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery. Clin. Cancer Res. 10, 4215s–4219s (2004).

86 Simon, G. et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 25, 2741–2746 (2007).

87 Chiappori, A. et al. Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer. Oncology 68, 382–390 (2005).

88 Ceppi, P., Papotti, M. & Scagliotti, G. New strategies for targeting the therapy of NSCLC: the role of ERCC1 and TS. Adv. Med. Sci. 55, 22–25 (2010).

89 Rothschild, S. I., Gautschi, O., Lara, P. N. Jr, Mack, P. C. & Gandara, D. R. Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer. Curr. Opin. Oncol. 23, 150–157 (2011).

90 Dzagnidze, A. et al. Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. J. Neurosci. 27, 9451–9457 (2007).

91 Su, Z. et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J. Mol. Diagn. 13, 74–84 (2011).

92 Orlow, I. et al. DNA damage and repair capacity in patients with lung cancer: prediction of multiple primary tumors. J. Clin. Oncol. 26, 3560–3566 (2008).

93 Gorlova, O. Y. et al. DNA repair capacity and lung cancer risk in never smokers. Cancer Epidemiol. Biomarkers Prev. 17, 1322–1328 (2008).

94 Wang, L. E. et al. DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy. J. Clin. Oncol. 29, 4121–4128 (2011).

95 Camps, C., Sirera, R., Iranzo, V., Taron, M. & Rosell, R. Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapy. Clin. Lung Cancer 8, 369–375 (2007).

96 Gurubhagavatula, S. et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J. Clin. Oncol. 22, 2594–2601 (2004).

97 de las Peñas, R. et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann. Oncol. 17, 668–675 (2006).

98 Matakidou, A. et al. Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Hum. Mol. Genet. 16, 2333–2340 (2007).

99 Shiraishi, K. et al. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. J. Clin. Oncol. 28, 4945–4952 (2010).

100 Lara, P. N. Jr et al. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin. Cancer Res. 11, 4444–4450 (2005).

101 Perez, R. P. et al. Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the CHK1 inhibitor UCN-01 (NSC 638850). Clin. Cancer Res. 12, 7079–7085 (2006).

102 Edelman, M. J. et al. Phase I and pharmacokinetic study of 7-hydroxystaurosporine and carboplatin in advanced solid tumors. Clin. Cancer Res. 13, 2667–2674 (2007).

103 Fink, D. et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 56, 4881–4886 (1996).